Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Suárez‐Calvet, Marc; K Karikari, Thomas; J Ashton, Nicholas; Lantero Rodríguez, Juan; Milà‐Alomà, Marta; Domingo Gispert, Juan; Salvadó, Gemma; Minguillon, Carolina; Fauria, Karine; Shekari, Mahnaz; Grau‐Rivera, Oriol; M Arenaza‐Urquijo, Eider; Sala‐Vila, Aleix; Sánchez‐Benavides, Gonzalo; Maria González‐de‐Echávarri, José; Kollmorgen, Gwendlyn; Stoops, Erik; Vanmechelen, Eugeen; Zetterberg, Henrik; Blennow, Kaj; Luis Molinuevo, José; the ALFA Study, for; Beteta, Annabella; Cacciaglia, Raffaele; Cañas, Alba; Deulofeu, Carme; Cumplido, Irene; Dominguez, Ruth; Emilio, Maria; Falcon, Carles; Fuentes, Sherezade; Hernandez, Laura; Huesa, Gema; Huguet, Jordi; Marne, Paula; Menchón, Tania; Operto, Grégory; Polo, Albina; Pradas, Sandra; Soteras, Anna; Vilanova, Marc; Vilor‐Tejedor, Natalia

doi:10.15252/emmm.202012921

Public

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Shared by NobleBlocks on Nov 10, 2020 • 12:00 AM UTC

Authors:

Marc Suárez‐Calvet

Thomas K Karikari

Nicholas J Ashton

Abstract

Abstract In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease evolution. The main aim of our study was to characterize the pattern of changes in phosphorylated tau (p‐tau) in...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!